Video

Dr. Park on Challenges With CAR T-Cell Therapies in AML

Author(s):

Jae H. Park, MD
Conference|PER® Congress on Hematologic Malignancies (Winter Hematology®)

Jae H. Park, MD, discusses a particular challenge he sees in using CAR T-cell therapies in patients with acute myeloid leukemia.

Jae H. Park, MD, attending physician, Leukemia Service and Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses a particular challenge he sees in using chimeric antigen receptor (CAR) T-cell therapies in patients with acute myeloid leukemia (AML).

For now, the data is still too early, but it has been encouraging, Park says, when looking at CD33 and CD123 in patients with AML. However, these targets are not as good as CD19. Park says further investigation is necessary to identify better targets in this space.

Related Videos
Areej El-Jawahri, MD, associate director, Cancer Outcomes Research and Education Program, director, Bone Marrow Transplant Survivorship Program, associate professor, medicine, Massachusetts General Hospital
Shyam A. Patel, MD, PhD
Amitkumar Mehta, MD
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Angeles A. Secord, MD, MHSc, professor, obstetrics and gynecology, Duke Cancer Institute, discusses findings from the phase 2 PICCOLO trial (NCT05041257) investigating mirvetuximab soravtansine-gynx (Elahere) in patients with recurrent, platinum-sensitive ovarian cancer with high folate receptor alpha (FRα) expression.
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School
Nicolas Girard, MD, professor, respiratory medicine, Versailles Saint Quentin University; head, Curie-Montsouris Thorax Institute, chair, Medical Oncology Department, Institut Curie
Breelyn Wilky, director, Sarcoma Medical Oncology, The Cheryl Bennett and McNeilly Family Endowed Chair in Sarcoma Research, deputy associate director, Clinical Research, associate professor, medicine, medical oncology, the University of Colorado Medicine
Related Content
Nizar Bahlis, MD
September 27th 2024

Talquetamab-Based Triplet Elicits Deep Responses in R/R Myeloma

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Vincenza Conteduca, MD, PhD
September 27th 2024

Radium-223 Before Docetaxel Demonstrates Better QOL in mCRPC, With No Difference in Survival

Matthew Lunning, DO, FACP
November 30th 2023

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

Meletios A. Dimopoulos, MD, of the National and Kapodistrian University of Athens School of Medicine
September 26th 2024

D-VRd Extends PFS in Newly Diagnosed Multiple Myeloma Subgroups

Verónica González-Calle, MD, MS, PhD
September 26th 2024

Belantamab Mafodotin Plus VRd Demonstrates Efficacy in Newly Diagnosed, Transplant-Eligible Myeloma